LIXTE Acquires Liora Technologies To Advance Next-Generation Proton Therapy and Oncology Innovation

LIXTE Biotechnology has finalized the acquisition of Liora Technologies Europe Ltd., a UK-based innovator developing electronically controlled proton therapy systems for cancer treatment. With this acquisition, Liora becomes a wholly owned subsidiary of LIXTE, expanding the company’s capabilities in advanced oncology technologies.

“The acquisition of Liora represents our entry in the radiotherapy segment of cancer care and marks a significant step in LIXTE’s corporate growth and development as we aim to fulfill our mission of treating cancer with cutting-edge technologies,” said Geordan Pursglove, CEO of LIXTE. “We believe that Liora’s flagship technology LiGHT System has significant global potential and could well set a new gold standard in cancer care, delivering high-precision proton therapy that is scalable and clinically versatile.”

“Our plan is to bring the LiGHT system to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model through jointly operated treatment centers. The addition of Liora also represents an excellent complement to the pharmaceutical side of our business and our ongoing clinical trials with LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer,” Pursglove added.

The deal brings Liora’s flagship LiGHT System (Linac for Image Guided Hadron Therapy) under LIXTE’s umbrella. This system offers notable advantages over current proton therapy platforms and is already installed at the Daresbury Laboratory operated by the UK’s Science and Technology Facilities Council (STFC). The facility will support the creation of a proton therapy center of excellence built around the LiGHT System.

Professor Steve Myers, former Director of Accelerators and Technology at CERN, the European Organization for Nuclear Research, said, “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors. In addition to the unique biological effects, it will also greatly reduce the installation cost and the number of treatment sessions needed, compared to current technologies, and is expected to significantly increase the number of patients that a treatment center can serve. With LIXTE’s acquisition of Liora’s assets, I am excited to see how the Company advances and scales this technology. I believe there is tremendous potential to turn this into a transformative new standard in cancer treatment.”

Alongside this acquisition, LIXTE continues to advance LB-100, its lead compound based on the novel concept of “activation lethality,” a fresh therapeutic approach supported by a strong patent estate. Ongoing proof-of-concept clinical trials are evaluating LB-100 in ovarian clear cell carcinoma and metastatic colon cancer, aiming to establish it as part of a new treatment paradigm in oncology.